The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | TAGS: impact of prior therapies on outcomes with trifluridine/tipiracil
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the result of a post-hoc analysis evaluating the impact of prior treatment on the outcomes of third-line chemotherapy in patients enrolled in the Phase III TAGS trial investigating trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
